Proteomics

Dataset Information

0

Differential activity of treatment with protein kinase inhibitors on tumor phosphotyrosine profiles in patients with advanced cancer

ABSTRACT: Mass spectrometry-based phosphoproteomics of tumor tissue lysates provides a potential personalized medicine approach based on its ability to identify activated signaling pathways and novel drug targets. We performed a pilot study (NCT01636908) to determine the effect of protein kinase inhibitors (PKIs) on tyrosine-(pTyr)-phosphoproteomic profiles of serial tumor biopsies in patients with advanced cancer. Tumor needle biopsies were analyzed from 31 patients with advanced cancer before and after 2 weeks treatment with sorafenib (SOR), erlotinib (ERL), dasatinib (DAS), vemurafenib (VEM), sunitinib (SUN) or everolimus (EVE). pTyr-Phosphoproteomics of pre- and on-treatment biopsies was performed by phosphotyrosine immunoprecipitation followed by LC-MS/MS.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Liver, Epithelial Cell, Prostate Cancer Cell, Skin, Colon, Pancreas, Kidney, Esophagus

DISEASE(S): Colon Cancer,Melanoma,Esophageal Cancer,Prostate Cancer,Pancreatic Cancer,Kidney Cancer,Hepatocellular Carcinoma

SUBMITTER: Sander Piersma  

LAB HEAD: Connie Ramona Jimenez

PROVIDER: PXD008032 | Pride | 2019-04-18

REPOSITORIES: pride

Json Xml

Dataset's files

Source:
Action DRS
MaxQuant_TXT_folder.zip Other
QE1_150303_OPL1013_RdH_pTyr_IP_ICK_sunitinib_A1.raw Raw
QE1_150303_OPL1013_RdH_pTyr_IP_ICK_sunitinib_B2.raw Raw
QE1_150303_OPL1013_RdH_pTyr_IP_ICK_sunitinib_C3.raw Raw
QE1_150303_OPL1013_RdH_pTyr_IP_ICK_sunitinib_D4.raw Raw
Items per page:
1 - 5 of 69
altmetric image

Publications

Identification of predictive biomarkers for targeted therapies requires information on drug exposure at the target site as well as its effect on the signaling context of a tumor. To obtain more insight in the clinical mechanism of action of protein kinase inhibitors (PKIs), we studied tumor drug concentrations of protein kinase inhibitors (PKIs) and their effect on the tyrosine-(pTyr)-phosphoproteome in patients with advanced cancer. Tumor biopsies were obtained from 31 patients with advanced ca  ...[more]

PMID: 32024067

Publication: 1/2

Similar Datasets

Proteomics Phosphoproteomics scaled-down to tumor biopsy level. Part 2: biopsies
2019-10-28 | PXD003814 | Pride
Proteomics Phosphoproteomics scaled-down to tumor biopsy level -part 1 cell line
2022-03-02 | PXD003808 | Pride
Proteomics Quantitative Tyr Phosphoproteomic Analyses of Tumor Adaptive Response to MAPK Inhibition
2021-05-11 | PXD021877 | Pride
Proteomics Associations between cellular energy and pediatric inflammatory bowel disease patient response to treatment
2021-08-26 | PXD024229 | Pride
Proteomics,Multiomics Ascending colon biopsies from pediatric patients
2018-11-06 | PXD005086 | Pride
Proteomics INKA, an integrative analysis pipeline for inference of hyperactive phosphokinases in mass spectrometry-based phosphoproteomics data
2019-04-18 | PXD009995 | Pride
Proteomics INKA, an integrative analysis pipeline for inference of hyperactive phosphokinases in mass spectrometry-based phosphoproteomics data
2019-04-18 | PXD006616 | Pride
Proteomics Proteomic characterization of human hepatocellular carcinoma (HCC) tumor biopsies
2022-03-14 | PXD025705 | Pride
Proteomics Time-resolved phosphoproteomic analysis of OT-I CD8+ T cells stimulated with MHC-I tetramers loaded with N4 agonist peptide
2020-07-09 | PXD016583 | Pride
Proteomics Human colon biopsies (healthy and Ulcerative Colitis) LC-MS/MS
2015-05-26 | PXD001608 | Pride